This clinical trial is focused on studying two diseases: ANCA vasculitis and end-stage renal disease. ANCA vasculitis is a condition where the immune system attacks the blood vessels, leading to inflammation. End-stage renal disease is the final stage of chronic kidney disease, where the kidneys can no longer function properly. The study is investigating the effects of stopping or continuing immunosuppressive therapy in patients with these conditions. Immunosuppressive therapy involves medications that reduce the activity of the immune system to prevent it from attacking the body.
The medications being studied include rituximab, azathioprine, prednisone, and mycophenolate mofetil. Rituximab is given as an injectable solution, while azathioprine, prednisone, and mycophenolate mofetil are taken orally in tablet form. The purpose of the study is to determine if stopping immunosuppressive therapy is better for patients with end-stage renal disease and ANCA vasculitis compared to continuing the standard maintenance therapy. The study will follow participants for 24 months to observe any severe events such as major relapses, severe infections, or death.
Participants in the study will be randomly assigned to either continue their current immunosuppressive therapy or to stop it. The study will monitor the health of the participants over the course of two years to see which approach leads to better outcomes. This research aims to provide valuable information on the best treatment approach for patients with these serious conditions.
France 
